Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS2300 Monotherapy or Combination in Advanced Malignancies
NCT05048134Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS2300 in solid tumor (advanced stage) (5 arms), sponsored by Hengrui. Primary endpoints: Dose Limiting Toxicity at 3 weeks, Adverse Events up to 3 years and 1 more. Started Oct 2021; status: terminated.
02
Drugs
HRS2300
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05048134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048134.